Core Viewpoint - 康诺亚-B (02162.HK) has entered into a placement and subscription agreement to sell and issue shares, aiming to raise approximately HKD 864 million for various purposes [1][2]. Group 1: Share Placement and Subscription - The total number of shares to be placed is 21.6 million, representing about 7.72% of the company's issued shares as of the announcement date [2]. - The subscription involves 19 million new shares, accounting for approximately 6.36% of the enlarged share capital post-placement and subscription [2]. - Following the completion of the placement and subscription, the selling shareholder's stake will decrease from about 27.79% to approximately 25.16% of the enlarged issued share capital [2]. Group 2: Pricing and Financial Details - The placement price is set at HKD 45.48 per share, which is a discount of approximately 6.52% compared to the closing price of HKD 48.65 on June 10 [2]. - The total expected proceeds from the subscription are approximately HKD 864 million, with net proceeds estimated at around HKD 854 million [2]. Group 3: Use of Proceeds - The net proceeds are planned to be allocated as follows: approximately 35% for R&D expenses related to CM512, CM518D1, and other pipelines; about 30% for the commercialization of the drug Siplizumab; around 25% for capital expenditures on manufacturing and R&D facilities; and 10% for general corporate and operational purposes [2].

认购所得款项净额(经扣除佣金及估计开支后)预期合共约为8.54亿港元。认购所得款项净额拟用于 (i)CM512、CM518D1及其他管线的研发开支;(ii)司普奇拜单抗的商业化;(iii)制造及研发设施的资本开支; 及(iv)一般公司及营运资金用途。 配售股份总数为2160万股，占公司于本公告日期已发行股份数目(即2.8亿股)约7.72%。认购股份数目为 1900万股，占经配发及发行认购股份扩大后的股份约6.36%(假设除已配发及发行的认购股份外，自本公 告日期起至配售及认购完成日期，公司已发行股份并无变动)。配售价每股股份45.48港元： (a) 较2025 年6月10日(即最后交易日)于联交所所报的收市价每股股份48.65港元折让约6.52%。 智通财经APP讯，康诺亚-B(02162)发布公告，于2025年6月11日，公司、补足卖方Moonshot Holdings Limited与牵头账簿管理人摩根士丹利亚洲有限公司及联席账簿管理人高盛(亚洲)有限责任公司及华泰金 融控股(香港)有限公司订立配售及认购协议，(i)补足卖方同意出售，而牵头账簿管理人及联席账簿管理 人个别同意作为补足卖方代理，促使承配人( ...